Previous Close | 27.97 |
Open | 28.50 |
Bid | 28.04 x 200 |
Ask | 28.10 x 800 |
Day's Range | 28.04 - 28.59 |
52 Week Range | 25.92 - 35.09 |
Volume | |
Avg. Volume | 2,853,266 |
Market Cap | 16.782B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | 11.10 |
EPS (TTM) | 2.53 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | 0.84 (3.00%) |
Ex-Dividend Date | May 16, 2024 |
1y Target Est | 45.50 |
Decoding the Financials and Future Prospects in Royalty Pharma's Latest 10-Q Filing
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We con
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIR